# REGENERON PHARMACEUTICALS, INC. (REGN) FY2024 Q3 Balance Sheet

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: As of 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-10-31, accession number 0001804220-24-000040
- Page: https://plicit.ai/financials/regn/fy2024-q3-balance-sheet
- Chart image: https://plicit.ai/charts/regn-fy2024-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 37,441,900,000 US dollars
- **Current assets**: 19,333,600,000 US dollars
- **Non-current assets**: 18,108,300,000 US dollars
- **Liabilities**: 8,116,000,000 US dollars
- **Current liabilities**: 3,661,000,000 US dollars
- **Non-current liabilities**: 4,455,000,000 US dollars
- **Equity**: 29,325,900,000 US dollars
- **Marketable securities**: 7,784,700,000 US dollars
- **Accounts receivable, net**: 6,107,100,000 US dollars
- **Inventories**: 3,018,000,000 US dollars
- **Cash and cash equivalents**: 2,011,800,000 US dollars
- **Prepaid expenses and other current assets**: 412,000,000 US dollars
- **Marketable securities**: 8,490,900,000 US dollars
- **Property, plant, and equipment, net**: 4,439,200,000 US dollars
- **Deferred tax assets**: 3,015,100,000 US dollars
- **Intangible assets, net**: 1,120,100,000 US dollars
- **Other noncurrent assets**: 1,043,000,000 US dollars
- **Accrued expenses and other current liabilities**: 2,536,500,000 US dollars
- **Deferred revenue**: 627,200,000 US dollars
- **Accounts payable**: 497,300,000 US dollars
- **Long-term debt**: 1,984,000,000 US dollars
- **Other noncurrent liabilities**: 1,543,600,000 US dollars
- **Finance lease liabilities**: 720,000,000 US dollars
- **Deferred revenue**: 207,400,000 US dollars
- **Retained earnings**: 30,755,200,000 US dollars
- **Additional paid-in capital**: 12,702,800,000 US dollars
- **Accumulated other comprehensive income (loss)**: 60,200,000 US dollars
- **Common stock - Common Stock**: 100,000 US dollars
- **Common stock - Class A Stock**: 0 US dollars
- **Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none**: 0 US dollars
- **Treasury Stock, at cost; 27.0 shares in 2024 and 25.5 shares in 2023**: negative 14,192,400,000 US dollars
- **Gross equity (calculated)**: 43,518,300,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.